Quick Takeaways
- Can-Fite BioPharma announced the publication of a peer-reviewed article in Frontiers in Veterinary Science highlighting positive study results for Piclidenoson in dogs with osteoarthritis
- The study showed that oral treatment with Piclidenoson led to statistically significant improvements in mobility and pain assessments, including Liverpool Osteoarthritis in Dogs (LOAD) scores, Visual Analog Scale (VAS) pain scores, and veterinarian-assessed lameness, while maintaining a favorable safety profile with no serious treatment-related adverse events reported
- Piclidenoson is being developed for veterinary indications by Vetbiolix under a licensing agreement with Can-Fite BioPharma potentially worth up to $325M in milestone and royalty payments. Vetbiolix is currently conducting an advanced Phase II clinical study evaluating the therapy as a potential oral disease-modifying treatment for canine osteoarthritis
Why It Matters?
Piclidenoson could open a new, higher‑value segment in the canine osteoarthritis market as one of the first oral, potentially disease‑modifying options rather than just another pain reliever.
If the ongoing Phase II trial confirms the positive, peer‑reviewed results, Vetbiolix and Can‑Fite will be well placed to compete for chronic OA management against NSAIDs and injectable biologics, expand the premium end of the pet pain market.
Source: Globenewswire
